Conference Day Two: May 8, 2025
8:00 am Registration & Light Breakfast
9:00 am Chair’s Opening Remarks
Expanding Discovery Platforms to Identify Novel Payload Candidates Faster
9:15 am Exploring Next-Generation Payload Diversity Beyond Cytotoxics to Diversify Immune-oncology MOAs
Synopsis
- Exploring an internal preclinical pipeline of small molecule payloads with conjugation potential
- Discussing matching target biology with payload choice and unique considerations for contemporary ADC design
- Differentiating modes of action and identifying therapeutic niches based off-target
9:45 am Discovery of Novel ADC Payloads to Combat Topo1 & Tubulin Inhibitor Resistant Tumors
Synopsis
- Assessing preclinical data for protein translation inhibitor payload demonstrating efficacy in tumors resistant to Topo1 and tubulin ADCs
- Learning about a discovery platform for natural product payloads with novel modes of action
- Discussing potential of other pipeline natural products for ADCs
10:15am Morning Networking Break & Poster Session
Synopsis
Take a break from formal presentations to connect with your peers in a relaxed environment to learn more about the industry’s latest research. If you wish to provide a poster to present, please get in contact with adc@hansonwade.com
Exploring Drug Repurposing & Translation to Conjugates to Differentiate Your IP
11:15 am How Clinical Signals From Oral Zelenirstat Apply to NMT Inhibitors as ADC Payloads: Leveraging Validated Mechanisms & a Known Safety Profile
Synopsis
- Discussing clinical data from FIC oral NMT inhibitor, zelenirstat, including survival benefits in patients with solid tumors and clinical response in lymphoma, that support the mechanism’s therapeutic potential
- Preliminary analysis of an extensive portfolio of potent NMTi ADC candidates
- Preliminary examination of in vitro ADC data on the potential NMTi-ADC activity against cancer cell lines
11:45 am Navigating the ADC Patent Landscape: Strategic Approaches to Taking Advantage of Key ADC Patent Expirations & Building ADC Patent Assets With & Without Traditional Payloads
Synopsis
- Analyzing the implications of traditional payload patent expiration on ADC development strategy
- Understanding opportunities for medicinal chemistry modifications to create novel IP around off-patent payloads
- Exploring strategic approaches to protecting novel ADC candidates and evaluating potential candidates against the patent landscape
12:15pm Lunch
Translating Payload Chemistry to Drive Clinical & Downstream Success
1:15 pm Accelerating Degrader-Antibody Conjugate Design Through Strategic Integration of Traditional ADC & Expertise in TPD
Synopsis
- Translating physicochemical property optimization strategies from traditional ADCs to address unique degrader payload solubility and stability challenges
- Leveraging established conjugation chemistry expertise while adapting linker design for degrader-specific payloads
- Developing novel preclinical assays to evaluate non-cytotoxic mechanisms of action and predict clinical efficacy
1:45 pm Roundtable Discussion: Breaking Bottlenecks in ADC Payload Design & Development
Synopsis
Join an interactive discussion with cross-functional peers tackling common bottlenecks in the development, optimization, and translation of ADC payloads, and uncover opportunities to accelerate ADC development from bench to market.
Explore topics such as:
- What early-stage strategies can help mitigate downstream challenges and increase candidate success rates for ADC payloads?
- How can cross-functional collaboration and processes be optimized to address challenges in linker-payload design and development?
- What lessons from past downstream challenges can inform the successful development and clinical of novel ADCs?
2:15pm Enhanced Networking Break
Synopsis
Discuss your learnings from the conference with fellow ADC professionals and exchange thoughts on the most valuable sessions and take-home lessons.
Payload Selection & Optimization Based on Tumor & Target Biology
2:45 pm Predictive Biomarker Integration for Better Payload Selection to Maximize ADC Success
Synopsis
- Integrating genomic and proteomic data with predictive biomarkers to develop a robust methodology for matching optimal payloads to specific tumor profiles
- Understanding the implications of a growing payload toolbox on payload selection and the potential therapeutic application
- Discussing combination drug approaches that enhance ADC payload efficacy through strategic scheduling and immune system modulation
3:15 pm From Target to Payload: Making Informed Choices to Maximize Therapeutic Potential
Synopsis
- Applying target biology insights to evaluate and benchmark payload candidates for therapeutic fit
- Optimizing payload and conjugation chemistry to align with target-specific requirements
- Addressing decision-making process and conditions for utilizing dual-drug ADCs